The complex intersection of medical marijuana, recreation, and science
A comprehensive Mayo Clinic review examined cannabis from medical, recreational, and policy perspectives, noting promising therapeutic potential alongside growing evidence of addiction risk and psychosis concerns.
Quick Facts
What This Study Found
This extensive review covered the full landscape of cannabis issues circa 2012. Historically, cannabis was widely prescribed by American physicians from the mid-19th century until federal restrictions began in the 1930s, culminating in Schedule I classification in 1970.
On the medical side, the discovery of the endocannabinoid system in the 1990s opened numerous pharmaceutical possibilities, but federal research restrictions hampered clinical trials. On the risk side, growing evidence showed marijuana's addictive potential, particularly in young people, and its ability to induce and exacerbate psychotic illness in susceptible individuals.
The review noted the unusual situation where public approval drove medical legalization without the scientific data normally required for a new medication.
Key Numbers
16 states had legalized medical cannabis at time of publication. THC isolated in 1964. Endocannabinoid system appreciated in the 1990s. Schedule I classification since 1970.
How They Did This
Comprehensive narrative review using PubMed searches across multiple cannabinoid-related keywords, with hand-searched bibliographies. Covered endocannabinoid system biology, clinical therapeutics, addiction, psychosis, and legislative history.
Why This Research Matters
This review captured a pivotal moment when medical marijuana legalization was advancing rapidly while scientific evidence lagged behind. It provided clinicians with a balanced assessment of both potential and risks.
The Bigger Picture
The tension between public enthusiasm and scientific rigor for medical cannabis has defined the field. This review articulated the core challenge: promising therapeutic potential exists alongside real risks, and the political environment has outpaced the evidence base.
What This Study Doesn't Tell Us
Single-author review from a clinical perspective. The broad scope necessarily sacrificed depth on individual topics. Published during a rapidly evolving legal landscape that has changed substantially since.
Questions This Raises
- ?Can federal research restrictions be loosened without undermining drug scheduling?
- ?How should clinicians advise patients in legalized states?
- ?Is the evidence gap closing between public approval and scientific validation?
Trust & Context
- Key Stat:
- Public approval drove legalization without standard scientific evidence requirements
- Evidence Grade:
- Comprehensive narrative review covering a broad literature. Provides balanced context but does not systematically assess evidence quality.
- Study Age:
- Published in 2012. The legal landscape has changed dramatically, with more states legalizing both medical and recreational cannabis.
- Original Title:
- Blurred boundaries: the therapeutics and politics of medical marijuana.
- Published In:
- Mayo Clinic proceedings, 87(2), 172-86 (2012)
- Authors:
- Bostwick, J Michael
- Database ID:
- RTHC-00547
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is medical marijuana supported by science?
At the time of this review, the endocannabinoid system's discovery opened many therapeutic possibilities, but federal restrictions limited clinical trials. Some conditions (chronic pain, MS spasticity) had reasonable evidence. For many others, evidence was preliminary.
What are the main risks of cannabis?
The review highlighted two primary concerns: addiction potential (particularly in young users, with about 9% of users developing dependence) and the ability to trigger or worsen psychotic illness in genetically susceptible individuals.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- how-much-weed-legally-possess-state-guide
- crossing-state-lines-with-weed-legal-felony
- medical-card-worth-it-2026-benefits-costs
- how-much-weed-legally-grow-home-state-rules
Cite This Study
https://rethinkthc.com/research/RTHC-00547APA
Bostwick, J Michael. (2012). Blurred boundaries: the therapeutics and politics of medical marijuana.. Mayo Clinic proceedings, 87(2), 172-86. https://doi.org/10.1016/j.mayocp.2011.10.003
MLA
Bostwick, J Michael. "Blurred boundaries: the therapeutics and politics of medical marijuana.." Mayo Clinic proceedings, 2012. https://doi.org/10.1016/j.mayocp.2011.10.003
RethinkTHC
RethinkTHC Research Database. "Blurred boundaries: the therapeutics and politics of medical..." RTHC-00547. Retrieved from https://rethinkthc.com/research/bostwick-2012-blurred-boundaries-the-therapeutics
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.